Statistics about Health, Pharma & Medtech in Sweden
Statistics
- Vicore Pharma Holding total equity 2021-2025
- Saniona total equity 2021-2025
- Egetis Therapeutics total assets 2021-2025
- Egetis Therapeutics total equity 2021-2025
- Nanologica liabilities 2021-2025
- Nanologica gross profit 2021-2025
- Vicore Pharma Holding liabilities 2021-2025
- BioInvent International total assets 2021-2025
- BioInvent International total equity 2021-2025
- Nanologica operating profit 2021-2025
- Saniona gross profit 2021-2025
- Vicore Pharma Holding operating profit 2021-2025
- Nanologica total equity 2021-2025
- Egetis Therapeutics operating profit 2021-2025
- Xvivo Perfusion liabilities 2021-2025
- Xvivo Perfusion total assets 2021-2025
- Xvivo Perfusion net cash 2021-2025
- Xvivo Perfusion net income 2021-2025
- Xvivo Perfusion total equity 2021-2025
- Xvivo Perfusion gross profit 2021-2025
- Xvivo Perfusion revenue 2021-2025
- Xspray Pharma liabilities 2021-2025
- Xspray Pharma net income 2021-2025
- Xvivo Perfusion operating profit 2021-2025
- Xspray Pharma total assets 2021-2025
- Xspray Pharma net cash 2021-2025
- Xspray Pharma operating profit 2021-2025
- Xspray Pharma total equity 2021-2025
- Xbrane Biopharma liabilities 2021-2025
- Xbrane Biopharma net income 2021-2025
- Xbrane Biopharma total assets 2021-2025
- Xbrane Biopharma net cash 2021-2025
- Xbrane Biopharma total equity 2021-2025
- Xbrane Biopharma gross profit 2021-2025
- Xbrane Biopharma operating profit 2021-2025
- Xbrane Biopharma revenue 2021-2025
- Vitrolife net income 2021-2025
- Vitrolife liabilities 2021-2025
- Vitrolife total equity 2021-2025
- Vitrolife total assets 2021-2025
- Vitrolife revenue 2021-2025
- Vitrolife net cash 2021-2025
- Vitrolife operating profit 2021-2025
- Vitrolife gross profit 2021-2025
- SynAct Pharma liabilities 2021-2025
- SynAct Pharma net cash 2021-2025
- SynAct Pharma total assets 2021-2025
- SynAct Pharma net income 2021-2025
- SynAct Pharma total equity 2021-2025
- Swedish Orphan Biovitrum liabilities 2021-2025
- SynAct Pharma operating profit 2021-2025
- Swedish Orphan Biovitrum total assets 2021-2025
- Swedish Orphan Biovitrum net cash 2021-2025
- Swedish Orphan Biovitrum net income 2021-2025
- Swedish Orphan Biovitrum revenue 2021-2025
- Swedish Orphan Biovitrum total equity 2021-2025
- Swedish Orphan Biovitrum operating profit 2021-2025
- Swedish Orphan Biovitrum gross profit 2021-2025
- Senzime liabilities 2021-2025
- Senzime net income 2021-2025
- Senzime total assets 2021-2025
- Senzime net cash 2021-2025
- Senzime revenue 2021-2025
- Senzime gross profit 2021-2025
- Senzime total equity 2021-2025
- Sedana Medical net income 2021-2025
- Sedana Medical liabilities 2021-2025
- Senzime operating profit 2021-2025
- Sedana Medical total assets 2021-2025
- Sedana Medical net cash 2021-2025
- Sedana Medical total equity 2021-2025
- Sedana Medical gross profit 2021-2025
- Sedana Medical operating profit 2021-2025
- Sedana Medical revenue 2021-2025
- SECTRA liabilities 2020-2024
- SECTRA net income 2020-2024
- SECTRA total assets 2020-2024
- SECTRA net cash 2020-2024
- SECTRA total equity 2020-2024
- SECTRA gross profit 2020-2024
- SECTRA revenue 2020-2024
- SECTRA operating profit 2020-2024
- RaySearch Laboratories liabilities 2021-2025
- RaySearch Laboratories net income 2021-2025
- RaySearch Laboratories total assets 2021-2025
- RaySearch Laboratories net cash 2021-2025
- RaySearch Laboratories operating profit 2021-2025
- RaySearch Laboratories revenue 2021-2025
- RaySearch Laboratories gross profit 2021-2025
- Q-Linea liabilities 2021-2025
- Q-Linea net income 2021-2025
- Q-Linea total assets 2021-2025
- Q-Linea net cash 2021-2025
- Q-Linea total equity 2021-2025
- Q-Linea revenue 2021-2025
- Q-Linea operating profit 2021-2025
- Q-Linea gross profit 2021-2025
- Orexo total assets 2021-2025
- Orexo net income 2021-2025
- Orexo liabilities 2021-2025